FDA relaxes drug approval standards: corporate influence accelerates market access over safety
Original framing: “FDA will drop two-study requirement for new drug approvals, aiming to speed access - Associated Press News” — AP News (via Google News)
The FDA’s move is a classic trickster gambit: it inverts its own mandate, claiming 'speed' as a virtue while masking corporate capture as 'innovation.' This absurdity exposes how solemn regulatory language ('public health first') conceals its opposite, revealing the regulatory body as a puppet of the very industries it’s meant to oversee.
This regulatory shift exemplifies global healthcare's tension between market forces and public health ethics.
Cross-cultural models and historical precedents reveal that safety frameworks evolve through cultural values, while corporate influence consistently prioritizes short-term gains over systemic health equity.